With the aim of improving efficiencies in trial conduct while ensuring participant safety, regulatory guidelines have recently undergone revision. The revision to the ICH Guideline for Good Clinical Practice (E6 R2) primarily addresses quality management with a focus on risk identification, evaluation, control, review and reporting. With the pending adoption of these revised guidelines, it’s time to evaluate how your organizational structure and processes will be affected.
Not sure if you want to exhibit at or attend the What Effect Does ICH E6 R2 Have On Risk-Based Monitoring And Overall Quality Risk Management?? See the panels below to get the information you need to make an informed decision.
|Conference/Event Dates:||10/05/2016 - 10/05/2016|
|Primary Industry:||Clinical Pharmacology|
|Other Industries:||Clinical Pharmacology, Professional Healthcare|
|Cost to Attend:||Free|
|Audience:||Senior professionals from phama and biotech companies interested in learning more about the ICH e6 R2 revisions and the impact it will have on their organizations -
Directors of Data Management
Directors of Clinical Operations
|Booth Size||Booth Cost||Available Amenities|
|Marketing Vehicles Allowed:||n/a|
|Other Booth Sizes Available: n/a|
How do I show up here?
Add a note here, it is only visible by you.